Ivo M. B. Francischetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ivo M. B. Francischetti has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Dongying Ma
Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA
6 shared publications- José Marcos Chaves Ribeiro
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
6 shared publications - Robson Queiroz Monteiro
Laboratório de Trombose, Inflamação e Câncer, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro (UFRJ), Brazil
6 shared publications Daniella M. Mizurini
Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
3 shared publicationsEd L. Galgo
Department of Pathology
3 shared publicationsJohn F. Andersen
Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA
3 shared publications
Latest Publications
- 9 October 2026
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 37 (7) , 378-381
Validation of a chromogenic assay to detect factor VIII inhibitors in hemophilia patients on emicizumab
Was not provided for this article.
- 9 October 2026
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 37 (7) , 378-381
Validation of a chromogenic assay to detect factor VIII inhibitors in hemophilia patients on emicizumab
Was not provided for this article.
- 9 February 2026
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (3) , 493-494
Fibrin‐Associated Large B‐Cell Lymphoma
- 9 February 2026
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (3) , 493-494
Fibrin‐Associated Large B‐Cell Lymphoma
- 22 July 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (11) , 3640-3647
Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
- 22 July 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (11) , 3640-3647
Glycoprotein VI is a receptor for the PF4/anti-PF4 IgG complex and contributes to platelet activation in heparin-induced thrombocytopenia (HIT)
- 17 April 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (7) , 2242-2254
Soluble P-selectin, but not circulating cell-free DNA, is a potential diagnostic biomarker in heparin-induced thrombocytopenia
- 17 April 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (7) , 2242-2254
Soluble P-selectin, but not circulating cell-free DNA, is a potential diagnostic biomarker in heparin-induced thrombocytopenia
- Open Access
- 3 April 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (2)
Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy
- 3 April 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (2)
Open AccessIdiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy
- 26 May 2023
- Published by Springer Nature in Journal of Hematopathology
- Vol. 16 (3) , 185-186
The lymph node in IgA vasculitis (Henöch-Schonlein purpura)
- 26 May 2023
- Published by Springer Nature in Journal of Hematopathology
- Vol. 16 (3) , 185-186
The lymph node in IgA vasculitis (Henöch-Schonlein purpura)
- Open Access
SARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection results in coagulation activation although it is usually not associated with consumption coagulopathy. D‐dimers are also commonly elevated despite systemic hypofibrinolysis. To understand these unusual features of coronavirus disease 2019 (COVID‐19) coagulopathy, 64 adult patients with SARS‐CoV‐2 infection (36 moderate and 28 severe) and 16 controls were studied. We evaluated the repertoire of plasma protease inhibitors (Serpins, Kunitz, Kazal, Cystatin‐like) targeting the fibrinolytic system: Plasminogen Activator Inhibitor‐1 (PAI‐1), Tissue Plasminogen Activator/Plasminogen Activator Inhibitor‐1 complex (t‐PA/PAI‐1), α‐2‐Antiplasmin, Plasmin‐α2‐Antiplasmin Complex, Thrombin‐activatable Fibrinolysis Inhibitor (TAFI)/TAFIa, Protease Nexin‐1 (PN‐1), and Neuroserpin (the main t‐PA inhibitor of the central nervous system). Inhibitors of the common (Antithrombin, Thrombin‐antithrombin complex, Protein Z [PZ]/PZ inhibitor, Heparin Cofactor II, and α2‐Macroglobulin), Protein C ([PC], Protein C inhibitor, and Protein S), contact (Kallistatin, Protease Nexin‐2/Amyloid Beta Precursor Protein, and α‐1‐Antitrypsin), and complement (C1‐Inhibitor) pathways, in addition to Factor XIII, Histidine‐rich glycoprotein (HRG) and Vaspin were also investigated by enzyme‐linked immunosorbent assay. The association of these markers with disease severity was evaluated by logistic regression. Pulmonary expression of PAI‐1 and Neuroserpin in the lungs from eight post‐mortem cases was assessed by immunohistochemistry. Results show that six patients (10%) developed thrombotic events, and mortality was 11%. There was no significant reduction in plasma anticoagulants, in keeping with a compensated state. However, an increase in fibrinolysis inhibitors (PAI‐1, Neuroserpin, PN‐1, PAP, and t‐PA/PAI‐1) was consistently observed, while HRG was reduced. Furthermore, these markers were associated with moderate and/or severe disease. Notably, immunostains demonstrated overexpression of PAI‐1 in epithelial cells, macrophages, and endothelial cells of fatal COVID‐19, while Neuroserpin was found in intraalveolar macrophages only. These results imply that the lungs in SARS‐CoV‐2 infection provide anti‐fibrinolytic activity resulting in a shift toward a local and systemic hypofibrinolytic state predisposing to (immuno)thrombosis, often in a background of compensated disseminated intravascular coagulation.
Open AccessSARS‐CoV‐2 infection results in upregulation of Plasminogen Activator Inhibitor‐1 and Neuroserpin in the lungs, and an increase in fibrinolysis inhibitors associated with disease severity
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection results in coagulation activation although it is usually not associated with consumption coagulopathy. D‐dimers are also commonly elevated despite systemic hypofibrinolysis. To understand these unusual features of coronavirus disease 2019 (COVID‐19) coagulopathy, 64 adult patients with SARS‐CoV‐2 infection (36 moderate and 28 severe) and 16 controls were studied. We evaluated the repertoire of plasma protease inhibitors (Serpins, Kunitz, Kazal, Cystatin‐like) targeting the fibrinolytic system: Plasminogen Activator Inhibitor‐1 (PAI‐1), Tissue Plasminogen Activator/Plasminogen Activator Inhibitor‐1 complex (t‐PA/PAI‐1), α‐2‐Antiplasmin, Plasmin‐α2‐Antiplasmin Complex, Thrombin‐activatable Fibrinolysis Inhibitor (TAFI)/TAFIa, Protease Nexin‐1 (PN‐1), and Neuroserpin (the main t‐PA inhibitor of the central nervous system). Inhibitors of the common (Antithrombin, Thrombin‐antithrombin complex, Protein Z [PZ]/PZ inhibitor, Heparin Cofactor II, and α2‐Macroglobulin), Protein C ([PC], Protein C inhibitor, and Protein S), contact (Kallistatin, Protease Nexin‐2/Amyloid Beta Precursor Protein, and α‐1‐Antitrypsin), and complement (C1‐Inhibitor) pathways, in addition to Factor XIII, Histidine‐rich glycoprotein (HRG) and Vaspin were also investigated by enzyme‐linked immunosorbent assay. The association of these markers with disease severity was evaluated by logistic regression. Pulmonary expression of PAI‐1 and Neuroserpin in the lungs from eight post‐mortem cases was assessed by immunohistochemistry. Results show that six patients (10%) developed thrombotic events, and mortality was 11%. There was no significant reduction in plasma anticoagulants, in keeping with a compensated state. However, an increase in fibrinolysis inhibitors (PAI‐1, Neuroserpin, PN‐1, PAP, and t‐PA/PAI‐1) was consistently observed, while HRG was reduced. Furthermore, these markers were associated with moderate and/or severe disease. Notably, immunostains demonstrated overexpression of PAI‐1 in epithelial cells, macrophages, and endothelial cells of fatal COVID‐19, while Neuroserpin was found in intraalveolar macrophages only. These results imply that the lungs in SARS‐CoV‐2 infection provide anti‐fibrinolytic activity resulting in a shift toward a local and systemic hypofibrinolytic state predisposing to (immuno)thrombosis, often in a background of compensated disseminated intravascular coagulation.
- 12 May 2022
- Published by Elsevier in Insect Biochemistry and Molecular Biology
- Vol. 146, 103785
Functional aspects of evolution in a cluster of salivary protein genes from mosquitoes
- 12 May 2022
- Published by Elsevier in Insect Biochemistry and Molecular Biology
- Vol. 146, 103785
Functional aspects of evolution in a cluster of salivary protein genes from mosquitoes